RIBB
S-4 filedDeal announcedLife supportRibbon Acquisition Corp.
Merging with DRC Medicine Inc.
1/7 of a right per unit. 7 units = 1 listed right. *R trades whole.
Deal announced 2025-07-01
Pulse
90
↓Life-support risk
0–100 vitality — and a read on how the book feels about this shell.
% done
44%
Path to close
Price
$10.87
Mkt 52.10M
What is Pulse?
SPAC Pulse measures the current vitality of a deal on a 0–100 scale. A new IPO starts near 50 — a healthy heart with room both ways. It is not weakening just because nothing has printed yet. Weakening is a tag for a slowing beat (stalling cadence), not a quiet shell. 10-Q / 10-K on time is a good beat; an NT is a deficiency. File the report late, then file the NT late, and Pulse falls — that is how public investors read whether management is on top of the shell. Filing recovers some of it. It never pretends the miss did not happen. When other new IPOs file that window on time, they are no longer equal — those shells are healthier. High readings mean the deal book is accelerating; low readings flag life-support risk. Full methodology lives on the desk.
Rate + Lead II · 25 mm/s
Pulse Timeline
Top trace is the Pulse rate. Bottom is the filing lead — R-wave when the rate lifts, QS when it slows. Height is the change.
- 07-20 S-4/A
- 07-22 S-4/A
- 07-24 S-4/A
- 08-03 S-4/A
- 08-14 10-Q
- 10-07 Now
Auto interpretation · Lead II printoutLife supportPulse 90
QRS is weak or missing. Cadence stalled, cash is thin, or the book went quiet.
Silent 65dBeats/90d 4Recent gap 5d
Marks on this strip
- 04-0143 ↓8NT (late notice). Late-notice. Housekeeping, scored as a miss until the 10-Q/10-K lands. -8
- 06-0586 →0Listing deficiency. Exchange notice that day. It belongs on this date, not today. Pulse does not double-haircut an already-slow book.
- 06-1589 ↑3S-4/A. Comments coming back. Beat sped up. +3
- 07-2089 →0S-4/A. Amendment printed. Pulse unchanged.
- 07-2292 ↑3S-4/A. Comments coming back. Beat sped up. +3
- 07-2492 →0S-4/A. Amendment printed. Pulse already had this pace — comments still coming back, no re-rate. 2 biz days from the last book print.
- 08-0392 →0S-4/A. Amendment printed. Pulse already had this pace — comments still coming back, no re-rate. 6 biz days from the last book print.
- 08-1492 →010-Q. Periodic report on time. unchanged
- 10-0790 ↓2Now. Amendment gaps are shrinking — the beat is speeding up. 65d since the last beat. -2
Impression: QRS is weak or missing. Cadence stalled, cash is thin, or the book went quiet.
- · Amendment gaps are shrinking — the beat is speeding up.
- · No S-4/F-4 beat in 65 days.
Unconfirmed machine read · not medical advice · not financial advice
Historical context
S-4 on file in the archive
Precedent from 27 names in the Pulse archive (closed, liquidated, and broken deals). Archive base rate is one input; live beat speed then moves Pulse. Not a forecast.
- Close rate
- 100%
- Median days left
- 105
- Archive n
- 27
Status
In Review
Exchange
Nasdaq
Rights
1/7
Warrants
No
CIK
0002035016
IPO date
2025-01-15
Market cap
52.10M
Days to deadline
—
SEC tickers
RIBB, RIBBR, RIBBU
Sponsor
—
S-4 / F-4 filer
Holdco · DRC Medicine Inc.
Fiscal year
December 31
Next filing
10-Q 2026-11-14
Vote
—
Schedule
What is due next
- Fiscal year
- Ends December 31 · 10-K cover
- This window
- 10-Q due 2026-08-14 · filed
- Next due
- 10-Q 2026-11-14Period 2026-09-30
- Pulse
- +6
10-Q for period ended 2026-06-30, due 2026-08-14. 10-Q 2026-08-14 on time (+6).
On time with this window. Pulse stays even with the other new listings that filed.
Meetings
No shareholder meeting dated in the Q&A or calendar.
Price history
Delayed exchange prints — common, rights, units, warrants when listed. Last price is in the header. This tape does not move Pulse.
Loading quotes…
Loading chart…
S-4 amendment timeline
Shrinking gaps mean the deal is progressing. The tag says whether that filing cleared a checklist, dropped a hurdle, or repriced the deal.
Merging company
On file
DRC Medicine Inc.
Close timing Q&A
Gap
no later than five
Meeting Q&A
Gap
No meeting Q captured.
Proxy card
Gap
No form of proxy in the exhibits yet.
10-Q / 10-K
On file
10-Q for period ended 2026-06-30, due 2026-08-14. 10-Q 2026-08-14 on time (+6).
- 8-K2026-08-17
CURRENT REPORT
- 10-Q2026-08-14
10-Q
- S-4/A2026-08-03
S-4/A — DRC Medicine Inc.
- S-4/A2026-07-24
S-4/A — DRC Medicine Inc.
- S-4/A2026-07-22
S-4/A — DRC Medicine Inc.
Show 35 more filings
- S-4/A2026-07-20
S-4/A — DRC Medicine Inc.
- 8-K2026-07-15
CURRENT REPORT
- S-4/A2026-06-15
S-4/A — DRC Medicine Inc.
- 8-K2026-06-10
CURRENT REPORT
- 8-K2026-06-09
CURRENT REPORT
- 8-K2026-06-05
CURRENT REPORT
- S-4/A2026-06-04
S-4/A — DRC Medicine Inc.
- S-4/A2026-05-20
S-4/A — DRC Medicine Inc.
- 10-Q2026-05-15
10-Q
- S-42026-05-08
S-4 — DRC Medicine Inc.
- 10-K2026-04-24
10-K/A
- 8-K2026-04-15
CURRENT REPORT
- 8-K2026-04-13
CURRENT REPORT
- 10-K2026-03-31
10-K
- 8-K2026-03-27
CURRENT REPORT
- 8-K2026-03-16
CURRENT REPORT
- 8-K2026-03-16
CURRENT REPORT
- 8-K2026-03-12
CURRENT REPORT
- 8-K2026-03-12
CURRENT REPORT
- 8-K2026-03-09
CURRENT REPORT
- 8-K2026-02-18
CURRENT REPORT
- 8-K2026-01-28
CURRENT REPORT
- 8-K2026-01-27
CURRENT REPORT
- 8-K2026-01-12
AMENDMENT NO. 1 TO FORM 8-K
- 8-K2026-01-09
CURRENT REPORT
- 10-Q2025-11-14
10-Q
- 10-Q2025-08-13
10-Q
- 8-K2025-07-01
Item 1.01 Entry Into A Material Definitive Agreement
- 4252025-07-01
CURRENT REPORT
- 10-Q2025-05-15
10-Q
- NT 10-K2025-04-01
NT 10-K
- 10-K2025-04-01
10-K
- 8-K2025-03-13
CURRENT REPORT
- 8-K2025-01-23
CURRENT REPORT
- 8-K2025-01-21
CURRENT REPORT
Your notes
Saved on this device only.
Journal
On RIBB
Journal
Latest journal
2026-08-24
SAMO files Q1 10-Q, reports $28k net loss from Jan 27 inception to Mar 31
Pre-IPO period shows $21.8k cash, $50k sponsor note, and $574k total liabilities against $571k assets.
2026-08-31
BCCQ 425 outlines $2.3B Ursa Major combination, $1.6B pre-money
Form 425 communication filed 31 Aug 2026 discloses proposed business combination terms and PIPE.
2026-08-31
BCCQ 425 details proposed Ursa Major combination at $1.6B consideration
Form 425 filed August 31 communicates terms of the business combination with Ursa Major Technologies, Inc. Registration statement on Form S-4 to follow.
2026-08-31
BCCQ 425 outlines Ursa Major deal at $2.3 billion equity value
Form 425 communication filed Aug. 31 details proposed combination with Ursa Major Technologies and related PIPE commitments.
- BCCQ 425 files on proposed Ursa Major combinationBCCQ · 2026-08-31
- HVII 425: ONE Nuclear executes binding LOI for 2.88 GW Project CaymanHVII · 2026-08-31
- BREZ Audit Committee concludes May 14, 2026 balance sheet cannot be relied upon; restatement requiredBREZ · 2026-08-31
- OCAC dismisses YCM CPA INC., appoints HYYH CPA. LLCOCAC · 2026-08-31
- SAMO Units separate; Class A shares and warrants begin individual trading on NYSESAMO · 2026-08-31